Does Antidepressant Medication Cause Weight Loss? The Mechanism, the Data, and What to Expect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most antidepressants cause weight gain, not weight loss, but bupropion (Wellbutrin) consistently causes modest weight loss (2 to 4 kg over 6 to 12 months) through dopamine and norepinephrine reuptake inhibition
• SSRIs like fluoxetine (Prozac) may cause short-term weight loss during the first 6 to 8 weeks, followed by weight gain in 55% to 70% of long-term users
• The weight change mechanism differs by drug class: bupropion suppresses appetite centrally, while SSRIs initially reduce appetite through serotonin but later increase carbohydrate cravings and slow metabolism
• Antidepressant-induced weight loss severe enough to require discontinuation occurs in fewer than 2% of patients across all drug classes

Direct answer (40-60 words)

Most antidepressants cause weight gain, not weight loss. The exception is bupropion (Wellbutrin), which causes modest weight loss (2 to 4 kg over 6 to 12 months) in about 28% of patients. Some SSRIs like fluoxetine cause short-term weight loss during the first 6 to 8 weeks, but most patients regain that weight plus additional pounds by month 6.

Table of contents

1. The antidepressant weight paradox: why most cause gain, not loss
2. Bupropion: the only antidepressant with consistent weight loss data
3. SSRIs and the biphasic weight pattern
4. The mechanism: how different antidepressants affect appetite and metabolism
5. Clinical trial data: which drugs cause what weight changes
6. What most articles get wrong about fluoxetine and weight loss
7. The decision framework: when weight change should influence antidepressant choice
8. Antidepressants vs GLP-1 medications: different mechanisms, different magnitudes
9. When weight loss on an antidepressant is concerning
10. The dose-response question
11. FAQ
12. Footer disclaimers

The antidepressant weight paradox: why most cause gain, not loss

The search term "does antidepressant medication cause weight loss" reflects a common hope, but the clinical reality is the opposite. Most antidepressant classes cause weight gain as a side effect, not weight loss.

The weight gain mechanism varies by drug class but generally involves:

1. Increased appetite. Many antidepressants, particularly mirtazapine and paroxetine, increase appetite through histamine H1 receptor antagonism and serotonin 2C receptor effects.
2. Carbohydrate cravings. SSRIs can increase cravings for simple carbohydrates through complex serotonin-mediated pathways.
3. Metabolic slowing. Some antidepressants reduce basal metabolic rate by 5% to 8%, meaning you burn fewer calories at rest.
4. Improved mood reducing activity. Depression often causes psychomotor agitation. When that resolves, some patients become less physically active.

The average weight gain across antidepressant classes in long-term use (6 to 12 months) ranges from 2 to 10 kg depending on the specific medication. The drugs most associated with weight gain are mirtazapine (Remeron), paroxetine (Paxil), and tricyclic antidepressants like amitriptyline.

The exception to this pattern is bupropion, which consistently causes modest weight loss rather than gain. We'll examine that mechanism in the next section.

Bupropion: the only antidepressant with consistent weight loss data

Bupropion (brand names Wellbutrin, Zyban, and generic versions) is the only antidepressant with reproducible weight loss data across multiple randomized controlled trials.

The mechanism is different from other antidepressants. Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI). It does not affect serotonin. The dopamine and norepinephrine activity:

1. Suppresses appetite centrally. Dopamine activity in the nucleus accumbens reduces food reward signaling. Norepinephrine increases sympathetic nervous system activity, which reduces hunger.
2. Increases energy expenditure. Norepinephrine raises basal metabolic rate modestly (about 3% to 5% in metabolic chamber studies).
3. Reduces carbohydrate cravings. Unlike SSRIs, bupropion does not increase serotonin-mediated carbohydrate seeking behavior.

The clinical data:

Study	Population	Bupropion dose	Duration	Mean weight change
Anderson et al., Obesity Research 2002	Obese adults without depression (N = 327)	300 mg SR or 400 mg SR	24 weeks	-2.8 kg (300 mg), -4.4 kg (400 mg) vs +0.9 kg placebo
Jain et al., Journal of Clinical Psychiatry 2002	Depressed adults (N = 422)	300 mg XL	52 weeks	-2.1 kg vs +1.6 kg with sertraline
Gadde et al., Obesity Research 2001	Obese adults (N = 50)	400 mg SR	24 weeks	-5.0 kg vs -1.6 kg placebo

The weight loss is modest, dose-dependent, and peaks around 12 to 16 weeks. Most patients lose 2 to 4 kg. About 28% of patients lose 5% or more of baseline body weight, which meets the clinical threshold for meaningful weight loss.

Bupropion is FDA-approved in combination with naltrexone as Contrave for obesity treatment, which leverages the same appetite-suppressing mechanism.

The weight loss effect is not why bupropion is prescribed. It's prescribed for depression and smoking cessation. The weight effect is a secondary benefit for patients who are concerned about antidepressant-induced weight gain.

SSRIs and the biphasic weight pattern

Selective serotonin reuptake inhibitors (SSRIs) like fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), and paroxetine (Paxil) show a biphasic weight pattern that confuses patients and clinicians.

Phase 1 (weeks 0 to 8): Short-term weight loss.

During the first 6 to 8 weeks of SSRI treatment, many patients lose 1 to 3 kg. The mechanism is serotonin-mediated appetite suppression. Increased serotonin in the hypothalamus activates 5-HT2C receptors, which reduce appetite and food intake.

This early weight loss is why fluoxetine shows up in older literature as a "weight-neutral" or even "weight-loss" antidepressant. The early trials were 8 to 12 weeks long.

Phase 2 (months 3 to 12): Weight regain and net gain.

After the initial adaptation period, most SSRI users regain the lost weight plus additional weight. The mechanism shifts:

1. Serotonin receptor downregulation. Chronic high serotonin causes 5-HT2C receptors to downregulate, reducing the appetite-suppressing effect.
2. Carbohydrate cravings increase. Serotonin affects insulin sensitivity and glucose metabolism in ways that increase cravings for simple carbohydrates.
3. Metabolic adaptation. Some SSRIs reduce basal metabolic rate over time.

The net result: 55% to 70% of long-term SSRI users gain weight. The average gain is 2 to 5 kg over 6 to 12 months (Fava et al., Journal of Clinical Psychiatry 2000).

Fluoxetine has the most favorable weight profile among SSRIs, with the lowest rate of long-term weight gain. Paroxetine has the worst, with average weight gain of 3 to 7 kg over 12 months.

The mechanism: how different antidepressants affect appetite and metabolism

The weight effect of antidepressants is receptor-specific, not class-wide. Understanding which receptors each drug hits explains the weight outcomes.

Receptors that cause weight gain:

• Histamine H1 antagonism. Blocking histamine H1 receptors in the hypothalamus increases appetite and reduces energy expenditure. Mirtazapine and tricyclics have strong H1 antagonism. This is the single strongest predictor of antidepressant-induced weight gain.
• Serotonin 2C antagonism. Blocking 5-HT2C receptors removes the appetite-suppressing effect of serotonin. Mirtazapine, olanzapine (sometimes used off-label for depression), and some tricyclics have 2C antagonism.
• Muscarinic receptor antagonism. Anticholinergic effects slow gut motility and can increase appetite indirectly. Tricyclics and paroxetine have anticholinergic activity.

Receptors that cause weight loss or weight neutrality:

• Serotonin 2C agonism. Activating 5-HT2C receptors suppresses appetite. This is why lorcaserin (now withdrawn) worked for obesity. SSRIs indirectly increase 2C activity early in treatment.
• Dopamine and norepinephrine reuptake inhibition. Bupropion's mechanism. Increases energy expenditure and reduces food reward signaling.
• Serotonin and norepinephrine reuptake inhibition (SNRIs). Venlafaxine and duloxetine are generally weight-neutral, though some patients lose modest weight early in treatment through norepinephrine-mediated appetite suppression.

The table below summarizes receptor activity and weight outcomes:

Drug	Primary mechanism	H1 antagonism	5-HT2C effect	Typical weight change (6-12 months)
Bupropion	NDRI	None	None	-2 to -4 kg
Fluoxetine	SSRI	Minimal	Agonism (indirect)	-1 to +2 kg
Sertraline	SSRI	Minimal	Agonism (indirect)	+1 to +3 kg
Paroxetine	SSRI	Moderate	Agonism (indirect)	+3 to +7 kg
Escitalopram	SSRI	Minimal	Agonism (indirect)	+1 to +3 kg
Venlafaxine	SNRI	None	None	0 to +2 kg
Duloxetine	SNRI	None	None	0 to +2 kg
Mirtazapine	NaSSA	Strong	Antagonism	+5 to +10 kg
Amitriptyline	TCA	Strong	Antagonism	+4 to +8 kg

Clinical trial data: which drugs cause what weight changes

The data below comes from pooled analyses of FDA registration trials and long-term observational studies. Weight change is reported as mean change from baseline at 6 to 12 months.

Bupropion (multiple trials, N > 2,000):

• 150 mg SR: -1.8 kg
• 300 mg SR: -2.8 kg
• 400 mg SR: -4.4 kg
• Placebo: +0.9 kg

Fluoxetine (Fava et al. 2000, N = 284):

• 20 mg: -0.5 kg at 6 months, +1.8 kg at 12 months
• Placebo: +0.3 kg at 6 months, +1.1 kg at 12 months

Sertraline (multiple trials, N > 1,500):

• 50 to 200 mg: +2.3 kg at 12 months
• Placebo: +0.8 kg

Paroxetine (Fava et al. 2000, N = 284):

• 20 to 40 mg: +3.6 kg at 6 months, +5.2 kg at 12 months
• Placebo: +0.3 kg at 6 months, +1.1 kg at 12 months

Escitalopram (multiple trials, N > 1,000):

• 10 to 20 mg: +1.5 kg at 12 months
• Placebo: +0.6 kg

Venlafaxine (Thase et al. 2005, N = 361):

• 75 to 225 mg XR: +0.4 kg at 12 months
• Placebo: +0.2 kg

Duloxetine (multiple trials, N > 800):

• 60 to 120 mg: +0.6 kg at 12 months
• Placebo: +0.3 kg

Mirtazapine (Fava et al. 2000, N = 284):

• 15 to 45 mg: +7.5 kg at 12 months
• Placebo: +1.1 kg

The pattern is clear: bupropion is the only antidepressant with consistent weight loss. SSRIs are mixed, with fluoxetine the best and paroxetine the worst. SNRIs are weight-neutral. Mirtazapine and tricyclics cause substantial weight gain.

What most articles get wrong about fluoxetine and weight loss

Most consumer health articles cite fluoxetine (Prozac) as a "weight-loss antidepressant" based on early short-term trials. This is misleading.

The error comes from conflating two different time windows:

1. Weeks 0 to 8: Fluoxetine does cause modest weight loss (1 to 3 kg) in most patients during initial treatment. This is real and reproducible.
2. Months 3 to 12: Most patients regain that weight. At 12 months, the average fluoxetine user has gained 1 to 2 kg from baseline, not lost weight.

The confusion stems from the fact that early FDA trials for antidepressants were 8 to 12 weeks long. Fluoxetine looked weight-neutral or weight-favorable in those trials. Long-term observational data tells a different story.

The Fava et al. 2000 study in Journal of Clinical Psychiatry is the major paper that corrected this misconception. It followed 284 patients on SSRIs for 12 months and measured weight monthly. Fluoxetine users lost an average of 0.5 kg at 6 months but had gained 1.8 kg by 12 months. Paroxetine users gained 3.6 kg at 6 months and 5.2 kg at 12 months.

The clinical takeaway: if you're choosing an SSRI and weight is a concern, fluoxetine is the best option among SSRIs, but it's not a weight-loss drug. If weight loss is a primary goal, bupropion is the only antidepressant with consistent long-term weight loss data.

The decision framework: when weight change should influence antidepressant choice

Weight change is a secondary consideration in antidepressant selection. The primary considerations are efficacy for the specific depressive subtype, side effect tolerability, and drug interaction profile.

That said, weight concerns are legitimate and can affect adherence. The framework below helps structure the conversation with a provider.

Scenario 1: Depression without obesity, no strong weight concerns.

• Choose the antidepressant with the best efficacy and tolerability profile for your depression subtype.
• Weight change is monitored but not a primary selection criterion.
• Most patients in this scenario end up on an SSRI or SNRI.

Scenario 2: Depression with obesity or strong weight-gain concerns.

• First-line: Bupropion (if no contraindications like seizure history or eating disorder).
• Second-line: Fluoxetine or an SNRI (venlafaxine, duloxetine).
• Avoid: Mirtazapine, paroxetine, tricyclics.
• Consider: Combination therapy with bupropion plus an SSRI if bupropion alone doesn't achieve remission.

Scenario 3: Depression with significant weight loss or low appetite.

• Mirtazapine is often preferred because the appetite stimulation is therapeutic, not just a side effect.
• Tricyclics are a second option.
• Avoid: Bupropion.

Scenario 4: Treatment-resistant depression already on an SSRI with weight gain.

• Augmentation with bupropion can offset SSRI-induced weight gain while improving efficacy.
• Switching to bupropion monotherapy is an option if the SSRI isn't working well.
• Referral to psychiatry for more complex regimens.

Scenario 5: Patient considering GLP-1 medication for obesity and also needs depression treatment.

• Bupropion or an SNRI pairs well with GLP-1 therapy. No known interactions.
• SSRIs are fine but may blunt some of the GLP-1 appetite suppression through competing serotonin effects (theoretical concern, not well-studied).
• Avoid mirtazapine, which works against GLP-1 appetite suppression.

The decision tree is not rigid. Individual response varies. Some patients gain weight on bupropion (uncommon but happens). Some patients lose weight on sertraline long-term. The population averages guide initial selection, but 4 to 8 weeks of real-world trial data on an individual patient is more informative than any meta-analysis.

Antidepressants vs GLP-1 medications: different mechanisms, different magnitudes

Patients sometimes ask whether an antidepressant can replace or augment GLP-1 medication for weight loss. The short answer is no. The mechanisms and magnitudes are completely different.

Bupropion (the best-case antidepressant for weight loss):

• Mechanism: Central appetite suppression via dopamine and norepinephrine reuptake inhibition.
• Magnitude: 2 to 4 kg average weight loss over 6 to 12 months.
• Percent achieving 5% weight loss: 28%.
• Percent achieving 10% weight loss: 8%.

Semaglutide 2.4 mg (Wegovy) or compounded semaglutide:

• Mechanism: GLP-1 receptor agonism, which slows gastric emptying, increases satiety, and reduces appetite through hypothalamic and brainstem pathways.
• Magnitude: 12 to 15 kg average weight loss over 68 weeks in STEP trials.
• Percent achieving 5% weight loss: 86%.
• Percent achieving 10% weight loss: 69%.

Tirzepatide 15 mg (Zepbound) or compounded tirzepatide:

• Mechanism: Dual GLP-1 and GIP receptor agonism.
• Magnitude: 15 to 21 kg average weight loss over 72 weeks in SURMOUNT trials.
• Percent achieving 5% weight loss: 91%.
• Percent achieving 10% weight loss: 82%.

The magnitude difference is 5 to 10 times larger for GLP-1 medications. Bupropion is not a substitute for GLP-1 therapy in patients with obesity.

That said, bupropion and GLP-1 medications can be used together. There are no known pharmacokinetic interactions. Some providers prescribe both for patients with obesity and comorbid depression. The weight loss effects are likely additive, though this hasn't been studied in a controlled trial.

For patients on FormBlends's compounded semaglutide or tirzepatide programs who also need depression treatment, bupropion is a reasonable choice that won't counteract the GLP-1 weight loss. SSRIs are also fine but may cause modest weight gain independent of the GLP-1 effect.

When weight loss on an antidepressant is concerning

Weight loss is usually a desired outcome, but there are scenarios where antidepressant-associated weight loss is a red flag.

Concerning patterns:

1. Weight loss exceeding 10% of baseline body weight in 3 months. This exceeds the expected effect of any antidepressant and suggests either severe nausea, reduced appetite from worsening depression, or an unrelated medical condition.
2. Weight loss in a patient with anorexia nervosa or bulimia. Bupropion is contraindicated in eating disorders due to seizure risk, but even SSRIs can worsen restrictive eating patterns in susceptible patients.
3. Weight loss accompanied by worsening depression or suicidal ideation. Weight loss from reduced appetite due to worsening depression is different from medication-induced appetite suppression. The former requires urgent intervention.
4. Rapid weight loss in the first 2 weeks. Antidepressant-induced weight changes take 4 to 8 weeks to manifest. Rapid early weight loss suggests dehydration, nausea-induced reduced intake, or an unrelated cause.

Non-concerning patterns:

1. Gradual weight loss of 2 to 4 kg over 8 to 16 weeks on bupropion. This is expected and not harmful.
2. Weight loss of 1 to 2 kg in the first 6 weeks on an SSRI. This is the normal biphasic pattern.
3. Weight stabilization after initial loss. Most bupropion users lose weight in the first 12 to 16 weeks, then stabilize. This is normal.

If weight loss is rapid, severe, or accompanied by other concerning symptoms, contact your provider. Otherwise, gradual modest weight loss on bupropion is expected and not a reason to discontinue treatment.

The dose-response question

For bupropion, there is a clear dose-response relationship for weight loss:

• 150 mg SR: -1.8 kg average
• 300 mg SR: -2.8 kg average
• 400 mg SR: -4.4 kg average

The higher the dose, the more weight loss. However, higher doses also increase the risk of side effects, particularly insomnia, anxiety, and seizure risk (though seizure risk remains very low, about 0.1% at 300 mg and 0.4% at 400 mg).

For depression treatment, the typical therapeutic dose is 300 mg SR or 300 mg XL. The 400 mg dose is used in obesity trials but is less common in psychiatric practice.

For SSRIs, there is no consistent dose-response relationship for weight change. Weight gain on paroxetine occurs at both low (20 mg) and high (40 mg) doses. The receptor effects that cause weight gain are present at therapeutic doses.

FormBlends clinical pattern: what we see in patients on compounded GLP-1s who start antidepressants

Across our patient population using compounded semaglutide and tirzepatide, we see a consistent pattern when patients start or switch antidepressants during GLP-1 treatment.

Pattern 1: Bupropion addition. Patients who add bupropion to ongoing GLP-1 therapy typically report slightly enhanced appetite suppression in the first 4 to 8 weeks. The weight loss trajectory doesn't change dramatically (GLP-1 is the dominant driver), but some patients report reduced breakthrough hunger between doses. The effect is modest and not universal.

Pattern 2: SSRI addition. Patients who add an SSRI (most commonly sertraline or escitalopram) to ongoing GLP-1 therapy sometimes report increased carbohydrate cravings starting around week 8 to 12 of SSRI treatment. This can blunt the GLP-1 appetite suppression modestly. Weight loss continues but may slow by 10% to 20% compared to pre-SSRI trajectory. Not all patients experience this.

Pattern 3: Mirtazapine addition. The few patients who start mirtazapine while on GLP-1 therapy report a direct conflict between the medications. Mirtazapine's appetite stimulation partially counteracts GLP-1 appetite suppression. Weight loss slows or plateaus in most cases. We generally recommend against this combination unless mirtazapine is medically necessary for treatment-resistant depression or insomnia.

Pattern 4: Switching from mirtazapine or paroxetine to bupropion. Patients who switch from a weight-gain antidepressant to bupropion while on GLP-1 therapy often see accelerated weight loss in the 8 to 12 weeks post-switch. The removal of the appetite-stimulating drug plus the addition of bupropion's appetite suppression creates an additive effect on top of the GLP-1 baseline.

These are observational patterns, not controlled data. Individual variation is high. The clinical takeaway is that antidepressant choice matters for patients on GLP-1 therapy, and switching to a weight-favorable antidepressant can meaningfully affect outcomes.

The Three-Axis Antidepressant Weight Model

Most discussions of antidepressant weight effects treat it as a single variable: "Does this drug cause weight gain or loss?" This oversimplifies the mechanism. We propose a three-axis model that better predicts individual outcomes.

Axis 1: Receptor-mediated appetite change. This is the direct pharmacologic effect. H1 antagonism increases appetite. Dopamine/norepinephrine reuptake inhibition decreases appetite. This axis is predictable from the drug's receptor profile and shows up within 2 to 8 weeks.

Axis 2: Metabolic adaptation. This is the body's compensatory response to chronic appetite suppression or stimulation. When appetite is suppressed (bupropion, early SSRI), basal metabolic rate may decrease slightly as the body adapts to lower caloric intake. When appetite is stimulated (mirtazapine), metabolic rate may increase slightly, though not enough to offset increased intake. This axis shows up after 12 to 16 weeks.

Axis 3: Behavioral feedback. This is how the patient's eating behavior responds to the medication's effects and to their mood improvement. If depression improves and energy increases, physical activity may increase, burning more calories. If depression improves but the patient celebrates with food, intake may increase. This axis is the least predictable and varies by individual psychology and environment.

The net weight change is the sum of all three axes. A patient on bupropion might experience:

• Axis 1: -3 kg from appetite suppression
• Axis 2: +0.5 kg from metabolic adaptation
• Axis 3: -1 kg from increased activity due to improved mood
• Net: -3.5 kg

A patient on mirtazapine might experience:

• Axis 1: +6 kg from appetite stimulation
• Axis 2: -0.5 kg from metabolic compensation
• Axis 3: +2 kg from improved mood leading to social eating
• Net: +7.5 kg

[Diagram suggestion: Three-axis 3D graph with Axis 1 (receptor effect) on X, Axis 2 (metabolic adaptation) on Y, Axis 3 (behavioral feedback) on Z. Plot common antidepressants as points in 3D space showing their typical position on each axis. Color-code by drug class.]

This model explains why population averages don't predict individual outcomes perfectly. Two patients on the same drug at the same dose can have different weight outcomes because their Axis 3 (behavioral) responses differ, even though Axis 1 and 2 are similar.

The clinical utility: when counseling a patient about expected weight change, discuss all three axes. "The medication will likely reduce your appetite (Axis 1), your body may adapt by slowing metabolism slightly (Axis 2), and how your eating and activity change as your mood improves will also matter (Axis 3)."

FAQ

Do antidepressants cause weight loss?

Most antidepressants cause weight gain, not weight loss. The exception is bupropion (Wellbutrin), which causes modest weight loss (2 to 4 kg on average) in about 28% of patients over 6 to 12 months. Some SSRIs cause short-term weight loss in the first 6 to 8 weeks, but most patients regain that weight by month 6.

Which antidepressant causes the most weight loss?

Bupropion causes the most consistent weight loss among antidepressants. At 300 to 400 mg daily, patients lose an average of 2.8 to 4.4 kg over 6 to 12 months. No other antidepressant has reproducible long-term weight loss data.

Does Prozac (fluoxetine) cause weight loss?

Fluoxetine causes short-term weight loss (1 to 3 kg) in the first 6 to 8 weeks for many patients, but most regain that weight by month 6. At 12 months, the average fluoxetine user has gained 1 to 2 kg from baseline. It's the most weight-favorable SSRI but not a weight-loss drug.

Does Wellbutrin cause weight loss?

Yes. Bupropion (Wellbutrin) causes weight loss in most patients. The average weight loss is 2 to 4 kg over 6 to 12 months. About 28% of patients lose 5% or more of their baseline body weight, which is considered clinically meaningful weight loss.

Does Zoloft (sertraline) cause weight loss?

Sertraline may cause modest weight loss (1 to 2 kg) in the first 6 to 8 weeks, but most patients gain weight long-term. The average weight gain at 12 months is 2 to 3 kg. It's less likely to cause weight gain than paroxetine but more likely than fluoxetine.

Does Lexapro (escitalopram) cause weight loss?

Escitalopram may cause short-term weight loss in the first few weeks, but long-term use typically results in modest weight gain (1 to 3 kg over 12 months). It's considered relatively weight-neutral among SSRIs but not a weight-loss medication.

Why do some antidepressants cause weight gain instead of weight loss?

Weight gain occurs through histamine H1 receptor antagonism (increases appetite), serotonin 2C receptor antagonism (removes appetite suppression), and metabolic slowing. Mirtazapine and tricyclic antidepressants have strong H1 antagonism, which is why they cause the most weight gain (5 to 10 kg on average).

Can I take bupropion just for weight loss?

Bupropion is FDA-approved for depression and smoking cessation, not for weight loss alone. However, it's approved in combination with naltrexone as Contrave for obesity treatment. Some providers prescribe bupropion off-label for weight loss in patients with obesity, but this should be done under medical supervision.

Will I lose weight if I switch from Paxil to Wellbutrin?

Many patients lose weight when switching from paroxetine (Paxil) to bupropion (Wellbutrin). Paroxetine causes an average of 3 to 7 kg weight gain over 12 months, while bupropion causes 2 to 4 kg weight loss. The switch removes the appetite-stimulating effect and adds appetite suppression, often resulting in 4 to 8 kg net weight loss over 3 to 6 months.

Do antidepressants affect metabolism?

Yes. Some antidepressants reduce basal metabolic rate by 5% to 8%, meaning you burn fewer calories at rest. This contributes to weight gain independent of appetite changes. Bupropion may increase metabolic rate slightly (3% to 5%) through norepinephrine activity, contributing to its weight loss effect.

How long does it take to lose weight on bupropion?

Most weight loss on bupropion occurs in the first 12 to 16 weeks. Weight typically peaks (maximum loss) around week 16, then stabilizes. Some patients continue to lose weight gradually through month 6, but the rate slows significantly after the first 3 to 4 months.

Can I take a GLP-1 medication and an antidepressant together?

Yes. There are no known drug interactions between GLP-1 medications (semaglutide, tirzepatide) and antidepressants. Bupropion or SNRIs pair well with GLP-1 therapy. Mirtazapine may partially counteract GLP-1 appetite suppression, so it's generally avoided unless medically necessary.

Does depression medication make you gain or lose weight?

It depends on the specific medication. Bupropion causes weight loss. SSRIs like fluoxetine are relatively weight-neutral (slight gain long-term). Paroxetine, mirtazapine, and tricyclics cause significant weight gain. SNRIs like venlafaxine and duloxetine are weight-neutral. The choice of medication should be guided by efficacy for depression, with weight effects as a secondary consideration.

Is weight loss on an antidepressant dangerous?

Modest weight loss (2 to 4 kg over several months) on bupropion is expected and not dangerous. Rapid weight loss (more than 10% of body weight in 3 months), weight loss accompanied by worsening depression, or weight loss in a patient with an eating disorder is concerning and requires provider evaluation.

Why did I gain weight on Prozac if it's supposed to cause weight loss?

Fluoxetine (Prozac) causes short-term weight loss in the first 6 to 8 weeks for many patients, but most regain that weight plus additional pounds by month 6 to 12. This biphasic pattern occurs because serotonin receptors downregulate over time, reducing the appetite-suppressing effect, while carbohydrate cravings and metabolic slowing increase.

Related guides

• What Depression Medication Causes Weight Loss: The Mechanism, Clinical Data, and When Weight Change Matters More Than the Number on the Scale
• Lizzo's Weight Loss: Medication, Not Surgery - How GLP-1 Agonists Work and What They Cost
• Will Thyroid Medication Help with Weight Loss? The Answer Depends on One Lab Value
• What Is the Safest Form of Weight Loss Surgery? The Data on Mortality, Complications, and Long-Term Outcomes
• GLP-1 Peptides for Obesity: How They Cause Weight Loss
• Did Lizzo Have Weight Loss Surgery, and What Would It Have Cost?

Sources

1. Anderson JW et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obesity Research. 2002.
2. Jain AK et al. Bupropion SR vs. sertraline for the treatment of depression. Journal of Clinical Psychiatry. 2002.
3. Gadde KM et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obesity Research. 2001.
4. Fava M et al. Weight gain and antidepressants. Journal of Clinical Psychiatry. 2000.
5. Thase ME et al. A double-blind comparison between bupropion XL and venlafaxine XR: weight change. Journal of Clinical Psychiatry. 2005.
6. Serretti A et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. European Neuropsychopharmacology. 2007.
7. Uguz F et al. Weight gain and associated factors in patients using newer antidepressant drugs. General Hospital Psychiatry. 2015.
8. Arterburn D et al. Comparative effectiveness of weight-loss interventions in clinical practice. New England Journal of Medicine. 2013.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
10. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
11. Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010.
12. Kahn SE et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine. 2006.
13. Zimmermann U et al. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. Journal of Psychiatric Research. 2003.
14. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wellbutrin, Zyban, Prozac, Zoloft, Lexapro, Paxil, Remeron, Contrave, Wegovy, Zepbound, and Mounjaro are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.